Evidence map›Paper›PMID 33454460›Full record

ArticleEuropean journal of radiology2021

The rate of breast fibroglandular enhancement during dynamic contrast-enhanced MRI reflects response to neoadjuvant therapy.

John Virostko, Garrett Kuketz, Erin Higgins, Chengyue Wu, Anna G Sorace, Julie C DiCarlo, Sarah Avery, Debra Patt, Boone Goodgame, Thomas E Yankeelov

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

John VirostkoDepartment of Diagnostic Medicine, University of Texas at Austin, Austin, TX, USA; Livestrong Cancer Institutes, University of Texas at Austin, Austin, TX, USA; Department of Oncology, University of Texas at Austin, Austin, TX, USA. Electronic address: jack.virostko@austin.utexas.edu.
Garrett KuketzDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Erin HigginsDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Chengyue WuDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Anna G SoraceDepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Julie C DiCarloInstitute for Computational Engineering and Sciences, University of Texas at Austin, Austin, TX, USA.
Sarah AveryAustin Radiological Association, Austin, TX, USA.
Debra PattTexas Oncology, Austin, TX, USA.
Boone GoodgameSeton Hospital, Austin, TX, USA; Department of Internal Medicine, University of Texas at Austin, Austin, TX, USA.
Thomas E YankeelovDepartment of Diagnostic Medicine, University of Texas at Austin, Austin, TX, USA; Livestrong Cancer Institutes, University of Texas at Austin, Austin, TX, USA; Department of Oncology, University of Texas at Austin, Austin, TX, USA; Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA; Institute for Computational Engineering and Sciences, University of Texas at Austin, Austin, TX, USA; Department of Imaging Physics, MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas at Austin · USLivestrong Foundation · USSeton Healthcare Family · USTexas Medical Association · USTexas Oncology · USUniversity of Alabama at Birmingham · US

Funding

Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant TherapyU01CA142565 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KARCZMAR, GREGORY S., NANDA, RITA · 2010 to 2019
$4.5M
INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCERU24CA226110 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LEWIS, MICHAEL T., RUBIN, DANIEL L · 2019 to 2023
$3.2M
Image Driven Multi-Scale Modeling to Predict Treatment Response in Breast CancerU01CA174706 · NCI · VANDERBILT UNIVERSITY · PI QUARANTA, VITO, YANKEELOV, THOMAS E · 2013 to 2018
$2.5M
Personalizing immunotherapy in HER2+ breast cancer through quantitative imagingR01CA240589 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C · 2020 to 2023
$1.6M
NCI NIH HHS R01 CA240589NCI NIH HHS U01 CA142565NCI NIH HHS U01 CA174706NCI NIH HHS U24 CA226110
6 · The paper itself

Abstract

purposeThis study assesses the rate of enhancement of breast fibroglandular tissue after administration of a magnetic resonance imaging (MRI) gadolinium-based contrast agent and determines its relationship with response to neoadjuvant therapy (NAT) in women with breast cancer.

methodWomen with locally advanced breast cancer (N = 19) were imaged four times over the course of NAT. Dynamic contrast-enhanced (DCE) MRI was acquired after administration of a gadolinium-based contrast agent with a temporal resolution of 7.27 s. The tumor, fibroglandular tissue, and adipose tissue were semi-automatically segmented using a manually drawn region of interest encompassing the tumor followed by fuzzy c-means clustering. The rate and relative intensity of signal enhancement were calculated for each voxel within the tumor and fibroglandular tissue.

resultsThe rate of fibroglandular tissue enhancement after contrast agent injection declined by an average of 29 % over the course of NAT. This decline was present in 16 of the 19 patients in the study. The rate of enhancement is significantly higher in women who achieve pathological complete response (pCR) after both 1 cycle (68 % higher, p < 0.05) and after 3-5 cycles of NAT (58 % higher; p < 0.05). The relative intensity of fibroglandular enhancement correlates with the rate of enhancement (R

conclusionThe rate of fibroglandular tissue enhancement declines over the course of therapy, provides novel information not reflected by tumoral measures, and may predict pathological response early in the course of therapy, with smaller declines in enhancement in women who achieve favorable response.

Indexed as

Breast NeoplasmsNeoadjuvant TherapyBreastContrast MediaFemaleHumansMagnetic Resonance ImagingContrast MediaBPEBreast cancerFibroglandularIpsilateralNAT

Identifiers

PMID33454460
PMCPMC7897312
OpenAlexW3118833599

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.